Why Farbe Firma is the Top Manufacturer of Atracurium Besylate Injection
- Maulik Sudani
- Jun 5
- 7 min read
Last Updated: June 5, 2026
TL;DR: Atracurium Besylate Injection — a sterile aqueous solution of the non-depolarising neuromuscular blocking agent atracurium besylate, supplied most commonly as a 10 mg/mL solution in 2.5 mL and 5 mL ampoules for intravenous administration — is a core anaesthesia and critical-care agent used to provide skeletal-muscle relaxation for tracheal intubation, to facilitate surgery and controlled mechanical ventilation, and to support intubated patients in intensive care. As a benzylisoquinolinium non-depolarising blocker, atracurium competitively blocks acetylcholine at the neuromuscular junction and is then inactivated by organ-independent Hofmann elimination and ester hydrolysis, making its offset largely independent of renal or hepatic function. Because the molecule is heat- and pH-sensitive and degrades on storage — it must be kept refrigerated at 2–8 °C and protected from light — its safety depends on a precise stability-indicating assay, strict control of the laudanosine and related-impurity profile, low particulate and endotoxin, tightly held pH and robust ampoule container-closure integrity, all supported by validated cold-chain handling. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Atracurium Besylate Injection at our Gujarat, India facility and supplies it to hospital pharmacy, anaesthesia, operating-theatre and critical-care services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Non-depolarising neuromuscular blocking agent (skeletal-muscle relaxant) — Atracurium Besylate Injection provides muscle relaxation for tracheal intubation, surgery and controlled ventilation, blocking acetylcholine at the neuromuscular junction and clearing by organ-independent Hofmann elimination, so recovery is largely independent of renal or hepatic function.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified cold-chain ampoule filling lines, dedicated control of the stability-indicating assay, the laudanosine and related-impurity profile, low pH, particulate and endotoxin for a heat- and pH-sensitive aqueous injection, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data under refrigerated (2–8 °C) storage, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready ampoule packaging and validated 2–8 °C cold-chain logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Atracurium Besylate Injection Demands a Premium Manufacturer
Atracurium Besylate Injection sits at the centre of modern anaesthesia and critical care. It is the non-depolarising muscle relaxant that anaesthetists reach for to provide the skeletal-muscle relaxation needed for tracheal intubation, to keep the surgical field still during an operation, and to support controlled mechanical ventilation — and that intensivists use to manage intubated patients in the ICU. Given intravenously, it produces predictable, intermediate-duration relaxation whose offset, uniquely, does not depend on the kidneys or liver. In each of these settings the patient is anaesthetised and ventilator-dependent, the anaesthetist needs an exact and reproducible dose, and the solution delivered from each ampoule must be accurate, sterile and reliably the same from unit to unit.
That clinical reality places exceptional demands on the manufacturer. Atracurium besylate is a heat- and pH-sensitive benzylisoquinolinium compound that degrades on storage by the very Hofmann elimination that clears it in the body, generating laudanosine and other related substances; it must be formulated at a low, stabilising pH, kept refrigerated at 2–8 °C and protected from light, and even then carries a defined, relatively short shelf life. The assay must be exact, the laudanosine and related-impurity profile must stay within tight limits across the cold-chain shelf life, and the solution must be particulate-free, low in endotoxin and sealed in an ampoule whose integrity is verified. Choosing an Atracurium Besylate Injection manufacturer that treats the stability-indicating assay, impurity profiling, pH control, particulate and endotoxin control, container-closure integrity and validated cold-chain handling as core engineering disciplines is what protects the patient on the operating table.
What Sets a World-Class Atracurium Besylate Injection Manufacturer Apart
A world-class manufacturer of Atracurium Besylate Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of atracurium besylate together with tight control of laudanosine and the related-substance and degradation-product profile by HPLC for a self-degrading molecule, robust aseptic filling of a low-pH, cold-chain aqueous solution into ampoules with verified container-closure integrity, and tender-ready dossier support backed by validated 2–8 °C cold-chain handling for a product procured largely through hospital-formulary, anaesthesia and ministry-of-health channels. It starts with the active — pharmacopoeial-grade atracurium besylate sourced from qualified, audited API makers, with full assay, laudanosine, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Formulation, filling and sealing then have to preserve both the assay and the dose against a molecule that is actively degrading. The bulk solution is compounded in water-for-injection at the low, stabilising pH that slows Hofmann elimination, kept cold and protected from light throughout, sterile-filtered through 0.22 µm membrane and filled aseptically into ampoules under ISO Class 5 air. The filling and sealing parameters are locked in the master batch record, because for a self-degrading neuromuscular blocker the assay, the pH and the laudanosine profile govern both the efficacy and the safety of every ampoule. Each ampoule is fusion-sealed and 100 % inspected for particulate matter, fill volume, seal quality and cosmetic defects; in-process and release testing confirm atracurium assay by validated HPLC, the laudanosine and related-substance profile, pH, clarity of the solution, and endotoxin is held well within limits so the injection is safe for intravenous administration.
Quality Systems Behind Every Atracurium Besylate Injection
Every Farbe Firma Atracurium Besylate Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of atracurium besylate against USP, BP, IP or EP reference standards, control of laudanosine, related substances and degradation products by HPLC, pH and osmolarity, clarity of the solution, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, fill-volume verification and container-closure integrity for the ampoule format. Certificates of analysis are issued with full traceability back to the API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated ampoule filling lines with 100 % inspection, validated cold rooms and a continuously monitored 2–8 °C cold chain, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because atracurium degrades by Hofmann elimination on storage and its assay, pH and laudanosine profile drive both efficacy and shelf life, we treat the stability-indicating HPLC assay, the pH and the laudanosine result as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under refrigerated long-term (5 °C ± 3 °C) and accelerated (25 °C / 60 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and the cold chain is validated from our cold room to the customer.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Atracurium Besylate Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across anaesthesia, neuromuscular, analgesic, anti-infective, critical-care and supportive-care categories. For Atracurium Besylate Injection specifically, we supply the 10 mg/mL solution in 2.5 mL and 5 mL ampoules under WHO-GMP, cold-chain conditions, with country-specific strengths, fill volumes and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the refrigerated-stability and laudanosine-impurity data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A refrigerated-stability and ICH Q1B photostability packages, assay and laudanosine/related-substances method-validation data, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate validated 2–8 °C cold-chain shipping and logistics. When a buyer needs Atracurium Besylate Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, cold-chain filling-line slot and temperature-controlled shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the filling suite; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating assay development, laudanosine and related-substance control, low-pH formulation, particulate and endotoxin control, container-closure integrity, photostability, cold-chain validation and shelf-life choices in real detail. For a self-degrading non-depolarising neuromuscular blocker given to anaesthetised, ventilator-dependent patients, where assay accuracy, pH and impurity control directly govern both relaxation and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Atracurium Besylate Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Atracurium Besylate Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified ampoule filling lines, qualified water-for-injection systems, a validated 2–8 °C cold chain, 100 % ampoule inspection and continuous environmental monitoring.
Which strengths and pack sizes of Atracurium Besylate Injection do you supply?
Our standard presentations are a 10 mg/mL sterile aqueous solution in 2.5 mL (25 mg) and 5 mL (50 mg) ampoules. Custom strengths, fill volumes, ampoule counts per pack and country-specific artwork are available under contract manufacturing agreements.
Does Atracurium Besylate Injection require cold-chain storage and shipping?
Yes. Atracurium besylate is heat- and pH-sensitive and degrades on storage, so it must be kept refrigerated at 2–8 °C and protected from light. Farbe Firma manufactures, stores and ships the product under a validated, continuously monitored 2–8 °C cold chain, and provides refrigerated-storage stability data in the dossier.
Can Farbe Firma support country-specific registrations for Atracurium Besylate Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A refrigerated-stability and ICH Q1B photostability packages, assay and laudanosine/related-substances method-validation data, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Atracurium Besylate Injection contract manufacturing?
MOQs vary by ampoule size, fill volume, cold-chain requirements, label complexity and dossier requirements. For our 2.5 mL and 5 mL presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments